Coherus BioSciences

For profitContributed to NMEWebsite ↗

Also known as: Coherus Biosciences, Inc. | Coherus BioSciences, Inc. | COHERUS BIOSCIENCES INC | Coherus BioSciences (parent company for Zao InteKrin)

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

May 1, 2014

First marketed drug

Nov 2, 2018

First NDA

Oct 27, 2023

Last known activity

Mar 31, 2025

Timeline

2010s

Jan 1, 2010
Coherus BioSciences— Founded
Feb 12, 2014
InteKrin Therapeutics, Inc.— Acquired

2020s

Dec 17, 2021
adalimumab— Marketing Organization
Dec 17, 2021
adalimumab— NDA Secondary Org
Sep 8, 2023
Surface Oncology— Acquired
Oct 27, 2023
toripalimab— NDA Organization

Drugs by trial phase (19 distinct, 21 trials)

Phase 4 (4 own, 0 via acquisition)

Phase 3 (2 own, 0 via acquisition)

Phase 2 (1 own, 8 via acquisition)

Phase 1 (3 own, 1 via acquisition)

Indications

Studied for

Marketed drugs (4)

Subsidiaries (2 direct, 2 total across the full acquisition tree)

Recent trials (20)

NCT06657144Lead sponsorPhase 1Mar 31, 2025
NCT06389526Lead sponsorPhase 1Feb 15, 2025
NCT06679985Lead sponsorPhase 2Nov 30, 2024
NCT06457503Lead sponsorPhase 4Nov 1, 2024
NCT05757492Lead sponsorPhase 1/Phase 2Apr 26, 2023
NCT02650973Study directorPhase 1Feb 1, 2016
NCT02650973Lead sponsorPhase 1Feb 1, 2016
NCT02489227Study directorPhase 3Aug 1, 2015
NCT02489227Lead sponsorPhase 3Aug 1, 2015
NCT02486939Study directorPhase 3Jul 1, 2015
NCT02486939Lead sponsorPhase 3Jul 1, 2015
NCT02418104Study directorPhase 1May 1, 2015
NCT02418104Lead sponsorPhase 1May 1, 2015
NCT02638038Study chairPhase 2Feb 1, 2015
NCT02385851Lead sponsorPhase 1Feb 1, 2015

Details

Founded: Redwood City, CA, US Jan 1, 2010
First NDA: Oct 27, 2023
Last known activity: Mar 31, 2025

Designations held

Orphan drug
Priority review
Breakthrough therapy